Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Autologous Hematopoietic Stem Cell Transplantation|Conditioning|Multiple Myeloma
DRUG: Busulfan (BU)|DRUG: Cyclophosphamide (CY)|DRUG: Etoposide (VP-16)|DRUG: Melphalan
OS, overall survival (OS), 3 year
relapse rate relapse rate, relapse rate, 3 year|DFS, disease-free survival (DFS), 3 year|TRM, transplant-related mortality (TRM), 3 year
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.